Theriva Biologics Q3 2026 Results: Net Loss of $1.47M, Loss Narrows
Theriva Biologics reported a net loss of $6.7 million for the nine months ended September 30, 2026, a significant improvement from the $21.7 million loss in the prior year period. The company generated $0.3 million in license revenue and substantially reduced operating expenses, while maintaining a cash balance of $8.5 million as of the end of the quarter.
- Key figure
- Net loss $1.47M